alexa Antibiotic Treatment of Urinary Tract Infections (UTIs) In Primary Care: An Italian Pilot Study | Open Access Journals
ISSN: 2329-6887
Journal of Pharmacovigilance
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Antibiotic Treatment of Urinary Tract Infections (UTIs) In Primary Care: An Italian Pilot Study

Silvia Ussai1*, Michele Rizzo2, Giovanni Liguori2, Paolo Umari2, Nicola Pavan2, Tommaso Cai3 and Roberto Luzzati4 and Carlo Trombetta2

1Department of Infectious Disease, University Hospital of Udine, Italy

2Department of Urology, University of Trieste, Trieste, Italy

3Department of Urology, Santa Chiara Regional Hospital, Trento, Italy

4Department of Infectious Disease, University of Trieste, Italy

Corresponding Author:
Silvia Ussai
Department of Infectious Disease, University Hospital of Udine
Piazzale della Misericordia 15, 33100, Udine, Italy
Tel: 0432559111
E-mail: [email protected]

Received Date: June 18, 2016; Accepted Date: July 06, 2016; Published Date: July 11, 2016

Citation: Ussai S, Rizzo M, Liguori G, Umari P, Pavan N, et al. (2016) Antibiotic Treatment of Urinary Tract Infections (UTIs) In Primary Care: An Italian Pilot Study. J Pharmacovigilance 4:215. doi: 10.4172/2329-6887.1000215

Copyright: © 2016 Ussai S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Pharmacovigilance

Abstract

Background: Urinary tract infections (UTIs) are extremely common. In the global scenario, due to the rise of antibiotic resistance worldwide, they present a substantial public health challenge. The aim of this cross-sectional study was to review antibiotic utilization in the management of UTIs in primary care practices in Italy. Materials and methods: Patients in Italian primary care settings with a confirmed diagnosis of UTI and receiving antibiotic therapy were enrolled in a cloud-based pharmacovigilance study. Results: The study included 5232 patients (3903 females, 1329 males) who had been prescribed antibiotics for UTI between July 2014 and December 2015. Quinolones were prescribed for 4889 patients (94%) as the first line treatment. In the 14-days follow-up period, 3181 patients (60%) received at least one different antibiotic medication. Fifty-eight percent (n=1844) of patients further received antibiotics on day 2 and day 3 of the follow-up period. Different quinolones and cephalosporins were the most prescribed medications in this sub-population. Conclusion: The study raises concerns about antibiotic and specifically quinolone overuse in Italian UTI outpatients. Policy-making bodies and professional societies should prioritize reducing the inappropriate use of antibiotics. This can be achieved through antimicrobial stewardship programs, which are one of the primary solutions to address the growing problem of antimicrobial drugs resistance.

Keywords

UTI; Antibiotic; Resistance; Quinolone

Introduction

Urinary tract infections (UTIs) have become the most frequent bacterial infections worldwide. It is estimated that UTIs contribute to seven million hospital visits, one million emergency consultations and more than 100.000 hospitalizations [1] annually in the U.S alone.

Primary care settings often diagnose and manage UTIs [2]. They often empirically manage a broad spectrum of pathologies from acute cystitis to pyelonephritis [3].

In addition, they care for a broad range of patients, ranging from low risk groups such as young adults to vulnerable populations such as elderly patients, pregnant women [4], spinal cord injury patients [5], and patients requiring permanent or intermittent bladder catheterization [6].

When deciding on empiric therapy for a UTI, local resistance patterns to antibiotics are an important factor in choice of therapy [7]. Given this consideration, antibiotic choice should be based not only on efficacy and safety [8], but also, on the concept that broadspectrum antibiotics should be spared in order to safeguard their future effectiveness [9].

Primary care providers are critical to appropriately using antibiotics to manage UTIs, as they manage the majority of cases [10]. Scientific societies propose guidelines and recommendations for UTI management, which are periodically reviewed. Despite of this, common clinical practices appear poorly adherents to the best practice recommendations. Audit control procedures are necessary to identify critical issues, sub-optimal behaviour and provide solution to problems.

Aim

The goal of this study was to perform an analysis of the antibiotics Italian UTI patients receive in primary care. Authors also assessed if changes were made to the empiric therapy within the first 14 days of treatment.

Materials and Methods

All the patients included in this analysis lived in the northeast of Italy. During the study period, the study population received a primary care evaluation, a diagnosis of UTI, and the prescription of at least one antibiotic drug.

Inclusion criteria

a. Patients in primary care setting receiving an antibiotic prescription during the study period (18 months) and confirmed for UTI diagnosis;

b. Patients aged 14 years and over;

c. Patients agreeing to participate in the program.

Therapy assessment

Electronic health records (EHR) of patients were obtained through a cloud-based service using a closed loop pharmacovigilance system that recorded and updated all antibiotics taken during treatment.

The EHR was designed to identify and maintain a single patient record for each subject, report patient demographic information, and to create and maintain patient-specific medications lists.

This EHR has security features allowing communication amongst all members of the health care team and the researchers.

The diagnosis of UTI was confirmed by reviewing patient charts. The authors also identified new antibiotic prescriptions within the first 14 days of diagnosis, specifically on days 2, 3, 7 and 14 of the followup period. Statistical analysis was performed using SAS© statistical package 9.3 (SAS Institute Inc., Cary, NC, USA).

Results

The study included 5232 patients (3903 females, 1329 males) who had been prescribed antibiotics for UTI management between July 2014 and December 2015. Graph 1 describes the age and gender distribution among the cohort.

Pharmacovigilance-Age-gender-distribution

Graph 1: Age and gender distribution, UTI cohort

Within the study, almost all infections were seen in adults over age 19, 99.4%. Women in the age group between 20 and 79 years of age had 76.9% of all infections.

The highest incidence of UTI in females was found in the age group between 30 and 59 years as more than 50% of the UTI cases were detected in this age group. In this study, 94% of the patients (n=4889) received a quinolone as the first line treatment for UTI (Graph 2). About 3% (n=169) received Cephalosporins and 2% received Betalactams.

Pharmacovigilance-antibiotics-UTI-treatment

Graph 2: Prevalence of use of antibiotics for UTI treatment

The other antibacterial drugs prescribed to patients included fosfomycin, macrolides, lincosamides and sterptogramines antibiotics. A total of 3181 patients (60%) further received one or more new antibiotics in the 14 days follow-up period (Graph 3).

Pharmacovigilance-antibiotic-prescription-UTI

Graph 3: Number of patients Vs Number of new antibiotic prescription for UTI

About 67% of the patients (n=2135) further received 1 additional antibiotic for UTI treatment. A total of 588 (18%) patients were prescribed 2 new medications and 399 patients (12.5%) received 3 to 6 additional drugs since the first prescription (Table 1).

No. of antibiotics No. of patients
1 2135
2 588
3 219
4 98
5 47
6 35
7 21
8 8
9 7
10 4
11 3
12 7
13 1
14 1
15 1
16 2
19 1
21 1
22 1
24 1
Total 3181

Table 1: Number of patients receiving additional antibiotics.

In this study, the 4 classes of antimicrobial drugs prescribed after empiric therapies were: beta-lactams, tetracycline, other quinolones, and cephalosporins. At days 2 and 3, about 58% of the patients (n=1844) had received new antibiotics; the new medications were primarily beta-lactams and cephalosporin (Graph 4). On day 7 a spike in the prescribing of alternative quinolones was seen. By the 14th day of the follow-up period, 23% (n=733) of the study cohort had received new antibiotic prescription, often tetracycline (Graph 5).

Pharmacovigilance-Percentage-patients-receiving-new-antibiotics

Graph 4: Percentage of patients receiving new antibiotics during the follow-up period

Pharmacovigilance-New-antibiotic-class-distribution

Graph 5: New antibiotic class distribution vs Follow-up days

Discussion

This is the first Italian cross-sectional pilot study performed in the primary care arena to study antibiotic management in UTI patients. The study population usually received quinolones (n=4889), and, to a lesser extent, cephalosporin and beta-lactams (n=345) as the first line of treatment. In the 14 days following the first prescription, 3181 patients were prescribed a different antibiotic. It was found that by day 2 and 3 of the follow-up, about 58% of patients had already started on new antibiotic. The study lacked adequate data about the clinical and microbiological details of the patient’s diagnosis, however, as most of the patients were adult females it was clinically concluded that for most patients the uncomplicated UTIs was most likely cystitis.

According to the European Urology Guidelines for UTIs, neither quinolones nor cephalosporins are appropriate for the empiric treatment of uncomplicated cystitis [11]. Clearly our work shows that these guidelines were generally not followed.

The study did not have sufficient access to patient data to determine why these changes were made; however, we believe urine culture results, persistent symptoms or worsening of symptoms all could explain the changes in therapy.

The new antibiotic prescriptions may have been based on the incomplete remission of the patients’ symptoms or due to the occurrence of drug related adverse events. Andrew Cole, in a recent survey in United Kingdom involving 1000 General Physicians (GP), found that 55% of the GPs unwillingly prescribed antibiotics under the pressure of patients or patients, even when antibiotic therapy is not considered necessary [12]. Potential antibiotic overuse raises concern about resistance to a particular UTI drug or class of antibiotics. This study reveals the need for robust drug utilization review program and guidelines in the primary care management of UTI.

Limitation

This study has a few clear limitations. Foremost, the study lacks adequate clinical and microbiological data to determine why antibiotics were changed or if adverse events occurred. Secondly, therapy was evaluated retrospectively based on patient’s files and some data may not have been recorded.

Conclusion

Our study clearly demonstrates that Italian primary-care physicians are not following best practices when empirically managing UTI’s and often change their prescribing patterns during therapy. Policymaking bodies and professional societies should prioritize, reducing the inappropriate use of antibiotics through antimicrobial stewardship programs, which is one of the primary solutions to address the growing problem of antimicrobial resistance.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 9576
  • [From(publication date):
    July-2016 - Nov 20, 2017]
  • Breakdown by view type
  • HTML page views : 9294
  • PDF downloads : 282
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords